The Tpl2 Kinase Regulates the COX-2/Prostaglandin E2 Axis in Adipocytes in Inflammatory Conditions

• Published in: Molecular endocrinology (Baltimore, Md.) Vol. 29; no. 7; pp. 1025 - 1036
• Main Authors: Berthou, Flavien, Ceppo, Franck, Dumas, Karine, Massa, Fabienne, Vergoni, Bastien, Alemany, Susana, Cormont, Mireille, Tanti, Jean-François
• Format: Journal Article
• Language: English
• Published: United States Endocrine Society 01.07.2015; Oxford University Press
• Subjects: 3T3-L1 Cells; Adipocytes - drug effects; Adipocytes - metabolism; Adipocytes - pathology; Animals; Arachidonate 5-Lipoxygenase - metabolism; Caspase 3 - metabolism; Coculture Techniques; Culture Media, Conditioned - pharmacology; Cyclic AMP Response Element-Binding Protein - metabolism; Cyclooxygenase 2 - genetics; Cyclooxygenase 2 - metabolism; Cytokines - metabolism; Dinoprostone - metabolism; Inflammation - pathology; Inflammation Mediators - metabolism; Interleukin-1beta - pharmacology; Lipopolysaccharides - pharmacology; Macrophage Activation - drug effects; Macrophages - cytology; Macrophages - drug effects; Macrophages - metabolism; MAP Kinase Kinase Kinases - antagonists & inhibitors; MAP Kinase Kinase Kinases - deficiency; MAP Kinase Kinase Kinases - metabolism; Mice; Mice, Inbred C57BL; NF-kappa B - metabolism; Original Research; Phosphorylation - drug effects; Protein Kinase Inhibitors - pharmacology; Proto-Oncogene Proteins - antagonists & inhibitors; Proto-Oncogene Proteins - deficiency; Proto-Oncogene Proteins - metabolism; RNA, Messenger - genetics; RNA, Messenger - metabolism; Signal Transduction - drug effects; Tumor Necrosis Factor-alpha - pharmacology
• ISSN: 0888-8809; 1944-9917
• DOI: 10.1210/me.2015-1027

Bioactive lipid mediators such as prostaglandin E2 (PGE2) have emerged as potent regulator of obese adipocyte inflammation and functions. PGE2 is produced by cyclooxygenases (COXs) from arachidonic acid, but inflammatory signaling pathways controlling COX-2 expression and PGE2 production in adipocytes remain ill-defined. Here, we demonstrated that the MAP kinase kinase kinase tumor progression locus 2 (Tpl2) controls COX-2 expression and PGE2 secretion in adipocytes in response to different inflammatory mediators. We found that pharmacological- or small interfering RNA-mediated Tpl2 inhibition in 3T3-L1 adipocytes decreased by 50% COX-2 induction in response to IL-1β, TNF-α, or a mix of the 2 cytokines. PGE2 secretion induced by the cytokine mix was also markedly blunted. At the molecular level, nuclear factor κB was required for Tpl2-induced COX-2 expression in response to IL-1β but was inhibitory for the TNF-α or cytokine mix response. In a coculture between adipocytes and macrophages, COX-2 was mainly increased in adipocytes and pharmacological inhibition of Tpl2 or its silencing in adipocytes markedly reduced COX-2 expression and PGE2 secretion. Further, Tpl2 inhibition in adipocytes reduces by 60% COX-2 expression induced by a conditioned medium from lipopolysaccharide (LPS)-treated macrophages. Importantly, LPS was less efficient to induce COX-2 mRNA in adipose tissue explants of Tpl2 null mice compared with wild-type and Tpl2 null mice displayed low COX-2 mRNA induction in adipose tissue in response to LPS injection. Collectively, these data established that activation of Tpl2 by inflammatory stimuli in adipocytes and adipose tissue contributes to increase COX-2 expression and production of PGE2 that could participate in the modulation of adipose tissue inflammation during obesity.